APA (7th ed.) Citation

GC, I., RA, L., TP, H., A, H., N, T., F, B., . . . JE, C. (2026). Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia. Haematologica. https://doi.org/10.3324/haematol.2025.300145

Chicago Style (17th ed.) Citation

GC, Issa, et al. "Favorable Tolerability of Asciminib Versus ATP-competitive Tyrosine Kinase Inhibitors in the ASC4FIRST Study of Newly Diagnosed Patients with Chronic-phase Chronic Myeloid Leukemia." Haematologica 2026. https://doi.org/10.3324/haematol.2025.300145.

MLA (9th ed.) Citation

GC, Issa, et al. "Favorable Tolerability of Asciminib Versus ATP-competitive Tyrosine Kinase Inhibitors in the ASC4FIRST Study of Newly Diagnosed Patients with Chronic-phase Chronic Myeloid Leukemia." Haematologica, 2026, https://doi.org/10.3324/haematol.2025.300145.